Resveratrol is a stilbene compound found in the skin of grapes and in Japanese knotweed, and it became one of the best-known “healthy ageing” ingredients after early laboratory research on cell ageing. Brands abroad ask for a Japan-made trans-resveratrol product on the strength of that reputation.
The reputation runs well ahead of the human evidence, and the compound itself is awkward to formulate because of how fast the body clears it. This guide sets out what bioavailability research and clinical trials actually show, what the EU’s novel food rules mean for a synthetic source, and what to decide before a Japan-made product.
Health supplements are foods, not medicines, and are not a substitute for medical treatment. Nothing here is a claim that any product prevents, treats or cures a disease.
💬 Planning a resveratrol product made in Japan? We check the full formula against Japanese food law first. See Japan-made supplement OEM.
Absorption is good, bioavailability is not
Trans-resveratrol is absorbed well by the gut but is broken down so quickly by the intestine and liver that almost none of it reaches the bloodstream unchanged.
| Study | Design | Reported result |
|---|---|---|
| Radiolabelled pharmacokinetic study, Drug Metabolism and Disposition 2004 (PMID 15333514) | Six healthy volunteers given a 25 mg oral dose of resveratrol | Absorption was at least 70%, but unchanged resveratrol in plasma stayed below 5 ng/mL; the authors attributed the very low bioavailability to extremely rapid sulfate conjugation in the intestine and liver |
That gap between absorption and bioavailability is the central formulation problem for resveratrol: the dose that reaches tissue as the parent compound is a small fraction of what is swallowed, and most of what circulates is metabolites whose own biological activity is still being studied.
What human clinical trials show
A 2024 systematic review of resveratrol clinical trials found the overall evidence inconclusive, with some biomarkers improving in some studies and not in others.
| Study | What it covered | Conclusion |
|---|---|---|
| Systematic review, International Journal of Molecular Sciences 2024 (PMID 38255828) | Clinical trials of resveratrol across multiple health outcomes over roughly 20 years of research | Concluded there is “no conclusive clinical evidence to advocate its recommendation in any healthcare setting,” and called for larger, higher-quality trials |
The review covered trials in a range of populations and outcomes, not a single ageing endpoint, and found the picture mixed rather than uniformly positive or negative. A brand that markets resveratrol as an ageing ingredient should describe it as a compound still under active clinical investigation, not as one with an established human benefit.
Checked against the published abstracts on 25 September 2026.
What Japanese products say
In Japan, resveratrol is mostly sold as a general food supplement without a functional claim; only a limited number of products have gone through the Foods with Function Claims notification process.
A general food in Japan may not describe a function or benefit on its label or in advertising. Only a business that notifies a specific product under the Foods with Function Claims system, or holds approval as a Food for Specified Health Uses, may state a function — and each notification covers that business’s own formula and evidence, not resveratrol as an ingredient in general.
💬 Need an evidence summary for your regulatory adviser that separates what can be said in Japan from what can be said elsewhere? We prepare it with the manufacturing documents. Tell us your market.
The EU novel food rule for synthetic trans-resveratrol
The European Union authorised a synthetically produced trans-resveratrol as a novel food ingredient with a maximum dose, an adults-only restriction, and a mandatory warning about interaction with medicines.
Under Commission Implementing Decision (EU) 2016/1190, this trans-resveratrol may be placed on the market in food supplements in capsule or tablet form, for the adult population only, at a maximum dose of 150 mg per day. The decision required label wording informing consumers that people taking medicines should use the product only under medical supervision, because of a possible interaction. The applicant demonstrated substantial equivalence to resveratrol from Japanese knotweed (Polygonum cuspidatum), which already has a history of consumption in the EU. Grape- and grape-seed-derived resveratrol supplements have also been sold in the EU at a range of doses without going through this specific authorisation, reflecting that history.
This is one EU decision covering one production route; a brand selling trans-resveratrol in the EU should confirm current novel food status and conditions for its own specific source and production method before finalising a formula, since rules for other resveratrol sources or later authorisations may differ.
Wording that stays on safe ground
Describe resveratrol by what has actually been studied, not by the “anti-ageing” shorthand the ingredient is known for.
| Safer wording | Wording to avoid |
|---|---|
| ”Contains trans-resveratrol” with the amount per serving | ”Reverses ageing” or “anti-ageing miracle" |
| "A compound studied in ageing-related research" | "Clinically proven” without naming the study and its limits |
| ”Sourced from Japanese knotweed” or “grape-derived”, stated accurately | Disease names, or “treats” any age-related condition |
How resveratrol is formulated
Because so little unchanged resveratrol reaches the bloodstream, dose, source and stability matter more than for many other ingredients.
| Dosage form | Why brands choose it | What to weigh up |
|---|---|---|
| Hard capsule | Protects resveratrol from light and oxidation until use | Light-resistant packaging still needed |
| Tablet | Familiar, cost-effective format | Formulation stability during compression |
Decisions that shape the specification:
- Source. Trans-resveratrol used in supplements is extracted from Japanese knotweed or grape by-products, or produced synthetically or by fermentation. State the source, since regulatory status can differ by source and market.
- Trans- vs cis- content. Specify the trans-resveratrol purity, since the trans form is the one studied in the trials above.
- Amount per serving. Match it to a market’s permitted maximum where one applies, such as the EU’s 150 mg/day limit for the specific novel food authorisation described above.
- Stability and packaging. Resveratrol degrades with light and heat exposure; agree packaging and storage conditions that protect the stated content through shelf life.
The check that comes first
Every ingredient must be permitted in foods in Japan, or a Japanese factory cannot make the product.
Trans-resveratrol used in foods is established in Japan. The questions that most often complicate a formula are the source (knotweed, grape or synthetic) and any market-specific dose limit like the EU’s, both of which need to be fixed before a factory can quote. See the Japan-made supplement OEM page, and compare with our NMN and CoQ10 guides for two other ingredients marketed around healthy ageing.
Before you ask for a quotation
A factory can quote accurately once the source, the trans-resveratrol amount, the form and the packaging are fixed.
- Resveratrol source (Japanese knotweed, grape, synthetic or fermentation-derived)
- Trans-resveratrol amount and purity per serving
- Dosage form and packaging
- Countries you will sell in, and any dose limit or novel food status there
- First order and annual volume
💬 Ready to design a Japan-made resveratrol product? Send us the concept — source, amount, form and the countries you will sell in.
Frequently asked questions
1. Does resveratrol actually slow ageing in humans?
The clinical evidence is currently inconclusive. A 2024 systematic review of resveratrol trials found no conclusive evidence to support its use in any healthcare setting, and called for larger, higher-quality trials. Describe resveratrol as studied in ageing-related research, not as a proven anti-ageing ingredient.
2. Why is resveratrol hard to formulate effectively?
Because very little of an oral dose reaches the bloodstream as unchanged trans-resveratrol. A pharmacokinetic study found absorption of at least 70% but plasma levels of unchanged resveratrol below 5 ng/mL, due to rapid metabolism in the intestine and liver.
3. Is synthetic trans-resveratrol allowed in the EU?
Yes, under specific conditions. A 2016 EU decision authorised a synthetically produced trans-resveratrol as a novel food for adults only, in capsule or tablet form, up to 150 mg per day, with a required label warning about use alongside medicines.
4. Is Japanese knotweed or grape the better source?
Both are used, and the EU’s synthetic-resveratrol authorisation was based on demonstrating equivalence to knotweed-derived resveratrol. The source affects regulatory status and sourcing documentation more than it affects the resveratrol molecule itself, which is chemically the same compound.
5. Can I make health claims for resveratrol in Japan?
Only if your product goes through Japan’s Foods with Function Claims notification, or holds Food for Specified Health Uses approval, with evidence for your specific formula. Most resveratrol products sold in Japan are general foods and may not carry a function claim.
Sources: “High absorption but very low bioavailability of oral resveratrol in humans”, Drug Metabolism and Disposition 2004 (PMID 15333514); “Resveratrol for the Management of Human Health: How Far Have We Come? A Systematic Review of Resveratrol Clinical Trials to Highlight Gaps and Opportunities”, International Journal of Molecular Sciences 2024 (PMID 38255828); Commission Implementing Decision (EU) 2016/1190 authorising trans-resveratrol as a novel food ingredient; Consumer Affairs Agency information on Foods with Function Claims. Checked on 25 September 2026.